-
公开(公告)号：EP1794149A2
公开(公告)日：2007-06-13
申请号：EP05850758.3
申请日：2005-09-14
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
发明人： BOLD, Guido , CAPRARO, Hans-georg , CARAVATTI, Giorgio , FLOERSHEIMER, Andreas , FURET, Pascal , MANLEY, Paul, W. , VAUPEL, Andrea , PISSOT SOLDERMANN, Carole , GESSIER, François , SCHNELL, Christian , LITTLEWOOD-EVANS, Amanda, Jane , KAPA, Prasad Koteswara , BAJWA, Joginder, S. , JIANG, Xinglong
IPC分类号： C07D403/12 , C07D413/12 , C07D239/46 , A61K31/505
CPC分类号： C07D239/47 , C07D403/12 , C07D413/12
摘要： The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
-
2.发明公开
公开(公告)号：EP2104733A2
公开(公告)日：2009-09-30
申请号：EP07867751.5
申请日：2007-12-13
申请人： NOVARTIS AG
发明人： BEUVINK, Iwan , HALL, Jonathan , WEILER, Jan , SCHNELL, Christian , MUELLER, Matthias , SCHINKE-BRAUN, Martina , SERLUCA, Fabrizio
IPC分类号： C12N15/11
CPC分类号： C12N15/113 , C12N2310/113 , C12N2310/141
摘要： The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.
-
公开(公告)号：EP3121278A1
公开(公告)日：2017-01-25
申请号：EP16174066.7
申请日：2007-05-02
申请人： NOVARTIS AG
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/317 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/332 , C12N2310/346 , C12N2310/3529 , C12N2310/50 , C12N2310/3521 , C12N2310/3533 , C12N2310/3525
摘要： Short interfering ribonucleic acid (siRNA), said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.
摘要翻译： 短干扰核糖核酸（siRNA），所述siRNA包含在至少15个核苷酸上彼此互补的两个单独的RNA链，其中每个链是49个核苷酸或更少，并且其中至少一个链含有至少一个化学修饰 。
-
公开(公告)号：EP3370719A1
公开(公告)日：2018-09-12
申请号：EP16794067.5
申请日：2016-10-31
申请人： Novartis AG
发明人： SCHNELL, Christian , FRITSCH, Christine , DI TOMASO, Emmanuelle , MASSACESI, Cristian , BLUMENSTEIN, Lars
IPC分类号： A61K31/4196 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/553 , A61K9/00 , A61P35/00
CPC分类号： A61K31/4439 , A61K9/0053 , A61K31/4196 , A61K31/437 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/553 , A61P35/00
摘要： A method of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of a phosphatidylinositol 3-kinase inhibitor compound or a pharmaceutically acceptable salt thereof once-per-day either on a continuous daily schedule or an intermittent schedule at about zero to about three hours prior to sleep; a therapeutic regimen comprising administration of said compound or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.
-
公开(公告)号：EP3121278B1
公开(公告)日：2018-07-18
申请号：EP16174066.7
申请日：2007-05-02
申请人： NOVARTIS AG
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/317 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/332 , C12N2310/346 , C12N2310/3529 , C12N2310/50 , C12N2310/3521 , C12N2310/3533 , C12N2310/3525
摘要： Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.
-
公开(公告)号：EP2037906A1
公开(公告)日：2009-03-25
申请号：EP07764828.5
申请日：2007-06-25
申请人： NOVARTIS AG
IPC分类号： A61K31/137 , A61P37/06 , A61K31/397
CPC分类号： C07C215/08 , A61K31/13 , A61K31/137 , A61K31/397
摘要： The present invention relates uses of an S1 P receptor modulator such as 2-substituted 2- amino- propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula (X) for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.014 秒)
